Stoke Therapeutics (NASDAQ:STOK) Shares Gap Down – Time to Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK) gapped down prior to trading on Monday . The stock had previously closed at $32.85, but opened at $27.40. Stoke Therapeutics shares last traded at $26.66, with a volume of 334,987 shares traded.

Wall Street Analysts Forecast Growth

STOK has been the topic of a number of analyst reports. Wedbush lifted their target price on shares of Stoke Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. JPMorgan Chase & Co. upped their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. Chardan Capital increased their target price on Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Finally, Loop Capital set a $35.00 price target on Stoke Therapeutics in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.10.

Stoke Therapeutics Stock Down 13.8%

The company has a market capitalization of $1.62 billion, a P/E ratio of 42.17 and a beta of 1.10. The business has a 50 day moving average of $30.17 and a 200 day moving average of $23.82.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. On average, research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, Director Adrian R. Krainer sold 40,472 shares of Stoke Therapeutics stock in a transaction on Friday, November 14th. The shares were sold at an average price of $26.98, for a total value of $1,091,934.56. Following the completion of the transaction, the director directly owned 364,246 shares of the company’s stock, valued at $9,827,357.08. This trade represents a 10.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward M. Md Kaye sold 13,430 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $32.27, for a total transaction of $433,386.10. Following the completion of the sale, the director owned 49,124 shares in the company, valued at approximately $1,585,231.48. This trade represents a 21.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 104,705 shares of company stock worth $3,070,910 over the last three months. 9.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STOK. SG Americas Securities LLC lifted its stake in shares of Stoke Therapeutics by 187.2% in the 4th quarter. SG Americas Securities LLC now owns 25,836 shares of the company’s stock valued at $820,000 after purchasing an additional 16,840 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Stoke Therapeutics by 36.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,227,723 shares of the company’s stock worth $38,968,000 after buying an additional 327,451 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Stoke Therapeutics by 12.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after buying an additional 1,313 shares during the period. Polar Capital Holdings Plc increased its position in Stoke Therapeutics by 49.8% during the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after acquiring an additional 439,824 shares during the last quarter. Finally, Parkman Healthcare Partners LLC bought a new position in Stoke Therapeutics during the third quarter valued at $5,875,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.